Platinum agent combination treatment for triple-negative breast cancer well tolerated in phase II clinical trial

9 diciembre 2014

New research shows that a combination of doxil, carboplatin and bevacizumab is a well-tolerated treatment regimen in patients with metastatic triple-negative breast cancer who received no prior treatment for their metastatic disease. The work also included genomic profiling to measure molecular correlates of response.